Bristol Myers Squibb Joins Big Pharmas Race to Dominate Oncology
–News Direct–
Source: Wikimedia Commons
Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan to acquire Mirati Therapeutics in a deal valued at up to $5.8 billion1.
This strategic move aims to enhance BMS's oncology portfolio with Mirati's compound, MRTX1719, which holds promise for certain lung cancers, was a key draw.
The acquisition received unanimous approval from both companies' boards of directors. Bristol Myers Squibb's CFO and CEO-elect, Chris Boerner, highlighted the importance of this move, emphasizing that the acquisition of Mirati is another substantial step in their endeavor to expand their diversif...
